XML 70 R58.htm IDEA: XBRL DOCUMENT
v3.22.4

Collaborations and Other Arrangements (Details) $ / shares in Units, $ in Thousands, € in Millions |  |  |  |  |  | 1 Months Ended | 3 Months Ended | 12 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Apr. 16, 2021 USD ($) $ / shares shares | Feb. 01, 2021 USD ($) | Jan. 13, 2020 USD ($) | Nov. 04, 2019 EUR (€) | May 02, 2019 | Mar. 31, 2022 USD ($) | Mar. 31, 2021 USD ($) | Dec. 31, 2022 USD ($) $ / shares | Dec. 31, 2022 EUR (€) | Dec. 31, 2021 USD ($) $ / shares | Dec. 31, 2020 USD ($) | Dec. 31, 2019 USD ($) | Dec. 31, 2019 EUR (€) | Dec. 30, 2022 $ / shares | Jun. 30, 2021 USD ($) | Apr. 14, 2020 $ / shares
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional milestone payments related to FDA approval |  |  |  |  |  |  |  | $ 25,000 |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  |  |  | 199,358 |  | $ 363,105 | $ 142,759 |  |  |  |  |
Accounts payable |  |  |  |  |  |  |  | 11,526 |  | 16,159 |  |  |  |  |  |
Accrued and other current liabilities |  |  |  |  |  |  |  | 50,097 |  | $ 48,127 |  |  |  |  |  |
Collaboration agreement, threshold royalty payments |  |  |  |  |  |  |  | $ 2,900 |  |  |  |  |  |  |  |
License Agreement Fee |  |  |  |  |  | $ 35,000 |  |  |  |  |  |  |  |  |  |
Common Stock Par Or Stated Value Per Share | $ / shares |  |  |  |  |  |  |  | $ 0.0001 |  | $ 0.0001 |  |  |  |  |  |
Share Price | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 7.92 |  | $ 14.82
Finite-Lived Intangible Asset, Useful Life |  |  |  |  |  |  |  | 10 years | 10 years |  |  |  |  |  |  |
Bioeq IP AG |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Initial term of agreement |  |  |  | 10 years |  |  |  |  |  |  |  |  |  |  |  |
Percentage of gross profits shared |  |  |  | 50.00% | 50.00% |  |  |  |  |  |  |  |  |  |  |
Bioeq IP AG | Licensed Products |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum aggregate milestone payments | € |  |  |  | € 12.5 |  |  |  |  |  |  |  |  |  |  |  |
Additional milestone payments related to FDA approval | € |  |  |  |  |  |  |  |  | € 2.5 |  |  |  |  |  |  |
Bioeq IP AG | Research and Development Expense [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront and milestone payment |  |  |  |  |  |  |  |  |  |  |  | $ 11,100 | € 10.0 |  |  |
Innovent Biologics (Suzhou) Co., Ltd. | Bevacizumab Licensed Product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreement, upfront amount paid |  |  | $ 5,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum aggregate milestone payments |  |  | $ 40,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Innovent Biologics (Suzhou) Co., Ltd. | Research and Development Expense [Member] | Bevacizumab Licensed Product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  |  |  |  |  | $ 1,100 | 7,500 |  |  |  |  |
Collaboration Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License Agreement Fee |  | $ 35,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreement | Anti-TIGIT Antibody and IL-2 cytokine |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreement , Maximum Payments On Attainment Of Certain Sales Thresholds For Each Option Program |  |  |  |  |  |  | $ 170,000 |  |  |  |  |  |  |  |  |
Junshi Biosciences |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum paid amount for co-development activities (per licensed compound) |  | $ 25,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
License Agreement Fee |  |  |  |  |  | $ 35,000 |  |  |  |  |  |  |  |  |  |
Collaboration agreement, royalty on net sales for each exercised option, percentage |  | 18.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement, Maximum aggregate one-time payment for achievement of milestones, for each option program |  | $ 85,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share Price | $ / shares | $ 20.06 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Unregistered shares | shares | 2,491,988 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate value | $ 50,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Period before the company can sell, transfer or make any short sale of common stock (in years) | 2 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value for the discount for lack of marketability (DLOM) |  |  |  |  |  |  |  | $ 9,000 |  |  |  |  |  |  |  |
Junshi Biosciences | Accrued and other current liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Co-development, regulatory and technology transfer costs |  |  |  |  |  |  |  | 8,400 |  | 1,900 |  |  |  |  |  |
Junshi Biosciences | Toripalimab |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreement, upfront amount paid |  | $ 150,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement, royalty on net sales, percentage |  | 20.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement, threshold royalty payments |  | $ 380,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value for the discount for lack of marketability (DLOM) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 9,000 |
Junshi Biosciences | Research and Development Expense [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  |  |  | $ 68,500 |  | $ 175,400 | $ 5,000 |  |  |  |  |
Junshi Biosciences | Research and Development Expense [Member] | Toripalimab |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment for the exclusive rights |  |  |  |  |  |  | $ 145,000 |  |  |  |  |  |  |  |  |

X
- Definition Additional milestone payments upon achievement of certain development and regulatory milestones. + References No definition available. + Details
Name: | chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Additional milestone payments upon achievement of with subject to FDA approval + References No definition available. + Details
Name: | chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents co-development, regulatory and technology transfer costs. + References No definition available. + Details
Name: | chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of maximum payments to be made on attainment of certain sales thresholds for each option program under the collaboration agreement. + References No definition available. + Details
Name: | chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of option exercise fee per program under the collaboration agreement. + References No definition available. + Details
Name: | chrs_CollaborationAgreementOptionExerciseFeePerProgram
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the percentage of royalty on net sales under the collaboration agreement. + References No definition available. + Details
Name: | chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales
Namespace Prefix: | chrs_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the percentage of royalty on net sales for each option program under the collaboration agreement. + References No definition available. + Details
Name: | chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram
Namespace Prefix: | chrs_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of threshold payments to be made on achievement on various milestones for each option program under the collaboration agreement. + References No definition available. + Details
Name: | chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of threshold royalty payments to be made under the collaboration agreement. + References No definition available. + Details
Name: | chrs_CollaborationAgreementThresholdRoyaltyPayments
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents costs associated to a collaboration agreement. + References No definition available. + Details
Name: | chrs_CollaborationCosts
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the fair value for the discount for lack of marketability (DLOM). + References No definition available. + Details
Name: | chrs_FairValueForDiscountForLackOfMarketability
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Initial term of agreement. + References No definition available. + Details
Name: | chrs_InitialTermOfAgreement
Namespace Prefix: | chrs_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the maximum paid amount for co-development activities. + References No definition available. + Details
Name: | chrs_MaximumAmountPaidCoDevelopmentActivities
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition percentage of profit shared. + References No definition available. + Details
Name: | chrs_PercentageOfGrossProfitsOnSales
Namespace Prefix: | chrs_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the period before the company can sell, transfer or make any short sale of common stock. + References No definition available. + Details
Name: | chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock
Namespace Prefix: | chrs_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents research and development rights for upfront payment for exclusive rights. + References No definition available. + Details
Name: | chrs_ResearchAndDevelopmentExpenseUpfrontPaymentForExclusiveRights
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Shares agreed to be issued under stock purchase agreement in connection with the collaboration agreement. + References No definition available. + Details
Name: | chrs_StockPurchaseAgreementSharesAgreedToBeIssued
Namespace Prefix: | chrs_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Value of shares agreed to be issued under stock purchase agreement in connection with the collaboration agreement. + References No definition available. + Details
Name: | chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents upfront and milestone payments. + References No definition available. + Details
Name: | chrs_UpfrontAndMilestonePayment
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 852 -SubTopic 10 -Section 55 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766 + Details
Name: | us-gaap_AccountsPayableCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_AccruedLiabilitiesCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Face amount or stated value per share of common stock. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 730 -Section 25 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Price of a single share of a number of saleable stocks of a company. + References No definition available. + Details
Name: | us-gaap_SharePrice
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=chrs_BioeqIPAGMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=chrs_InnoventBiologicsSuzhouCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=chrs_BevacizumabLicensedProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=chrs_ExclusiveLicenseAndCommercializationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=chrs_AntiTigitAntibodyAndIl2CytokineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=chrs_JunshiBiosciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=chrs_AccruedAndOtherCurrentLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=chrs_ToripalimabMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |